{"id":"NCT01895309","sponsor":"Samsung Bioepis Co., Ltd.","briefTitle":"A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","officialTitle":"A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2014-04","completion":"2015-10","firstPosted":"2013-07-10","resultsPosted":"2016-08-29","lastUpdate":"2017-08-17"},"enrollment":596,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Enbrel (etanercept)","otherNames":[]},{"type":"DRUG","name":"SB4 (proposed biosimilar to etanercept)","otherNames":[]}],"arms":[{"label":"SB4 (proposed biosimilar to etanercept)","type":"EXPERIMENTAL"},{"label":"Enbrel (etanercept)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB4 compared to Enbrel in subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX) therapy. In some countries, after 52 weeks of treatment with either SB4 or Enbrel, subjects will be enrolled into an open label extension period. Subjects will receive SB4 for an additional 48 weeks.","primaryOutcome":{"measure":"American College of Rheumatology 20% Response Criteria (ACR20)","timeFrame":"Week 24","effectByArm":[{"arm":"SB4 (Proposed Biosimilar to Etanercept)","deltaMin":78.1,"sd":null},{"arm":"Enbrel (Etanercept)","deltaMin":80.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":2,"countries":["Poland","United Kingdom"]},"refs":{"pmids":["32468892","31958281","28968793","28794078","26150601"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":299},"commonTop":["Upper Respiratory Tract Infection","Injection Site Erythema","Alanine Aminotransferase Increased","Nasopharyngitis","Hypertension"]}}